Biocon Unit Secures USFDA Nod for Rare Disease Drug Generic
Overview
Biocon Pharma has received U.S. Food and Drug Administration (USFDA) approval for its generic Everolimus tablets for oral suspension. The drug targets rare genetic conditions like tuberous sclerosis complex, bolstering Biocon's specialty drug portfolio in the lucrative U.S. market.
Stocks Mentioned
Biocon Ltd announced Monday that its subsidiary, Biocon Pharma Ltd, has secured approval from the U.S. Food and Drug Administration (USFDA) for its generic version of Everolimus tablets for oral suspension. This development marks a significant step for the Indian biopharmaceutical firm in expanding its presence in the U.S. market.
Regulatory Milestone
The approval was granted for an Abbreviated New Drug Application (ANDA) and covers the drug in 2 mg, 3 mg, and 5 mg strengths. This clearance is a testament to Biocon's capabilities in developing complex generic formulations.
Therapeutic Application
Everolimus tablets for oral suspension are indicated for specific rare genetic conditions. They are used to treat adult and pediatric patients aged one year and above with Tuberous Sclerosis Complex (TSC), a disorder characterized by non-cancerous tumors in various organs. The drug also aids in the adjunctive treatment of TSC-associated partial-onset seizures in patients aged two years and older.
Market Expansion
This USFDA clearance is expected to further strengthen Biocon's portfolio of vertically integrated drug products. The company has been strategically expanding its offerings in complex generics and biosimil segments, aiming to tap into high-value therapeutic areas and enhance its global revenue streams.
